Aflibercept injections

This video summarizes interesting data from an aqueous vascular endothelial growth factor (VEGF) study presented at this year’s ARVO congress, in Seattle, US (Monday 02 May 2016, 16:45-17:00 PM, Program Number 2317). Patients with diabetic macular edema (DME) received either bimonthly intravitreal injections of ranibizumab (n=12) or aflibercept (n=7). Investigators Sawada et al. from Shiga University reported a significant reduction in median aqueous VEGF concentration from 141.9 pg/mL to 70.0 pg/mL 2 months after ranibizumab injection (P<0.05). Median aqueous VEGF concentration decreased from 160.1 pg/mL to below the lower limit of detection in six of seven eyes, and to 25.7 pg/mL in one eye 2 months after aflibercept injection (P<0.05). The investigators concluded that intravitreal aflibercept injections suppressed VEGF more than ranibizumab injections for 2 months.